TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Recommendation of “Moderate Buy” by Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has been assigned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $122.70.

TMDX has been the subject of a number of recent research reports. Piper Sandler cut their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Canaccord Genuity Group decreased their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Robert W. Baird dropped their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. TD Cowen reduced their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th.

Insider Activity at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now directly owns 732 shares in the company, valued at $61,158.60. This trade represents a 90.22 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is owned by company insiders.

Institutional Trading of TransMedics Group

Several hedge funds have recently modified their holdings of the company. Driehaus Capital Management LLC grew its position in shares of TransMedics Group by 15.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after buying an additional 202,867 shares during the last quarter. Geode Capital Management LLC grew its holdings in TransMedics Group by 1.3% in the third quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock worth $119,938,000 after purchasing an additional 10,106 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of TransMedics Group by 5.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock worth $94,061,000 after purchasing an additional 30,092 shares in the last quarter. Vaughan Nelson Investment Management L.P. lifted its holdings in shares of TransMedics Group by 24.3% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after purchasing an additional 64,360 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of TransMedics Group by 2.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after purchasing an additional 6,634 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Stock Up 9.2 %

Shares of TMDX stock opened at $61.97 on Friday. The company’s fifty day simple moving average is $70.17 and its two-hundred day simple moving average is $116.33. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $177.37. The stock has a market cap of $2.08 billion, a P/E ratio of 65.93 and a beta of 2.12. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The firm had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. TransMedics Group’s quarterly revenue was up 63.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.12) earnings per share. Analysts predict that TransMedics Group will post 1 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.